The current role of continuous BTK inhibitors in CLL treatment: benefits and drawbacks

Описание к видео The current role of continuous BTK inhibitors in CLL treatment: benefits and drawbacks

Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses the current role of continuous BTK inhibitors in chronic lymphocytic leukemia (CLL) treatment, highlighting the benefits and drawbacks of continuous therapy. BTK inhibitors offer the benefit of being highly effective and convenient for patients, however, there are drawbacks to this approach, including treatment-related toxicities and financial toxicity. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео